WebProNews

The American Stock Exchange (Amex) today listed the common stock of Samaritan Pharmaceuticals, Inc. under the ticker symbol LIV.

Samaritan Pharmaceuticals, Inc. is a development stage biotechnology company engaged in the research and development of novel therapeutic and diagnostic products to treat chronic debilitating diseases such as Alzheimer's, Cancer, central nervous system disorders, cardiovascular disease and HIV.

"We are pleased to welcome Samaritan Pharmaceuticals to the American Stock Exchange," said John McGonegal, senior vice president of the Amex Equities Group. "Samaritan is an innovator within the biotechnology industry and we look forward to working with them to increase investor attention and provide the support a growing company needs in today's competitive marketplace."

Samaritan President and CEO Janet Greeson stated, "By being listed on the Amex, Samaritan hopes to achieve greater accessibility to the institutional investment community; improved share price stability and liquidity; and broader investor awareness." Samaritan CFO Eugene Boyle further stated, "Our listing on the Amex opens a new chapter in Samaritan's history and is a major part of our strategy to attract new investors and increase the visibility of Samaritan."